The following pages link to (Q5714616):
Displaying 22 items.
- Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach (Q93669) (← links)
- Optimization in a multivariate generalized linear model situation (Q1023815) (← links)
- Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials (Q2320854) (← links)
- Adaptive designs for selecting drug combinations based on efficacy-toxicity response (Q2475724) (← links)
- Optimizing the concentration and bolus of a drug delivered by continuous infusion (Q2893431) (← links)
- A Bayesian Approach to Dose-Response Assessment and Synergy and Its Application to In Vitro Dose-Response Studies (Q3076068) (← links)
- A Bayesian approach for generalized linear models with explanatory biomarker measurement variables subject to detection limit: an application to acute lung injury (Q3168305) (← links)
- A utility approach to individualized optimal dose selection using biomarkers (Q3299111) (← links)
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios (Q3436524) (← links)
- Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates (Q3549405) (← links)
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials (Q3576931) (← links)
- Implementation of a Bayesian Design in a Dose‐Escalation Study of an Experimental Agent in Healthy Volunteers (Q5450494) (← links)
- gBOIN‐ET: The generalized Bayesian optimal interval design for optimal dose‐finding accounting for ordinal graded efficacy and toxicity in early clinical trials (Q6068828) (← links)
- A semiparametric Bayesian approach to population finding with time‐to‐event and toxicity data in a randomized clinical trial (Q6074511) (← links)
- Review and Comparison of Computational Approaches for Joint Longitudinal and Time‐to‐Event Models (Q6086623) (← links)
- TITE-gBOIN-ET: time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes (Q6572287) (← links)
- REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors (Q6618357) (← links)
- A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications (Q6622241) (← links)
- CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome (Q6625779) (← links)
- Hybrid design evaluating new biomarkers when there is an existing screening test (Q6627744) (← links)
- Change-point joint model for identification of plateau of activity in early phase trials (Q6627755) (← links)
- A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials (Q6627894) (← links)
